Leadership
-
Making Moves
Regenxbio CEO to step down after 15 years
Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.
By Ned Pagliarulo • June 13, 2024 -
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.
By Michael Gibney • June 11, 2024 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Behind Big Pharma’s layoffs — is there an end in sight?
A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?
By Kelly Bilodeau • June 10, 2024 -
Pharma’s R&D gamble: picking pipeline winners in a risky field
How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.
By Meagan Parrish • June 7, 2024 -
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Q&A
In an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
By Amy Baxter • June 3, 2024 -
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024 -
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.
By Michael Gibney • May 30, 2024 -
Can robots break the cell therapy bottleneck?
A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.
By Michael Gibney • May 29, 2024 -
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.
By Michael Gibney • May 23, 2024 -
After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era
Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.
By Alexandra Pecci • May 21, 2024 -
Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies
Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said.
By Amy Baxter • May 20, 2024 -
Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large
Execs from J&J, Novartis, Novo Nordisk and AbbVie sound off on the Inflation Reduction Act, supply issues and launch preparations in a tricky environment.
By Michael Gibney • May 16, 2024 -
Q&A
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024 -
Profile
Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off.
By Michael Gibney • April 30, 2024 -
Q&A
How a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
By Amy Baxter • April 29, 2024 -
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.
By Jacob Bell • April 24, 2024 -
Q&A
How pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
By Michael Gibney • April 11, 2024 -
Women want to participate in clinical trials. Lack of flexibility is still a problem.
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.
By Kelly Bilodeau • April 8, 2024 -
Sponsored by Avenga
Unlocking growth: How GenAI can help pharma companies convert new clients
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to $2258.1 million by 2032.
By Olena Domanska, Data Science Engineering Manager at Avenga • April 8, 2024 -
Q&A // First 90 Days
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
By Michael Gibney • April 4, 2024 -
Q&A
To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
By Alexandra Pecci • April 1, 2024 -
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.
By Ben Fidler • March 28, 2024 -
Q&A
SQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
By Gwendolyn Wu • March 26, 2024